This month marked the crystal anniversary of the life sciences networking event Knowledge for Growth. The event was a huge success, with 1300+ attendees representing 600+ companies from 20+ countries around the world. The theme for this year was “Precision in Life Sciences”, with the fascinating plenary talks discussing the effect of digitalization on healthcare.
Just days before KBC Securities’ "State of the Union" announcement on how well Belgian biotech has been faring in 2019, Confo Therapeutics closed a terrific series A financing round. The company raised 30 million euros, which will be used to accelerate their drug discovery activities using their camelid-based ConfoBody™ technology.
Belgium has once again strengthened its position as Europe's biotech leader. Today, Belgian biotech companies comprise 23 percent of the total market value of all public European biotech companies. Compared to the end of April 2018, the value of Belgian biotech companies increased by 12.5 percent from 24 to 27 billion euros. A few Belgian biotech giants such as Galapagos, argenx and UCB, are responsible for this growth. This according to figures announced by KBC Securities during the "State of the Union" event of the Flemish biotech sector federation flanders.bio and VIB on the eve of the large "knowledge for growth" congress in Ghent.
Have you ever considered how scientists are able to count transparent cells in a see-through solution? Traditional methods involve dyes, microscopes, time and effort. Now there’s a new technology on the market: Ovizio Imaging Systems has developed a technical solution to this longstanding problem. Using an imaging technique called digital holographic microscopy, Ovizio’s devices perform cell counts by reconstructing 3D images using light. This new type of imaging provides quantitative information about cells, including their number, morphology and viability, all without a drop of dye!
Bioscience engineers at KU Leuven have created a record-breaking hydrogen gas panel. The panel is capable of producing 250 liters of hydrogen gas per day; enough that just 20 panels could provide a family’s electricity and heating needs for a whole European winter. The Belgian device is an innovative step forward for clean energy and sustainability around the globe.
The Spanish start-up Minoryx Therapeutics recently opened a subsidiary in Belgium to further their research on treatments for rare and orphan diseases. Co-founder and CEO Marc Martinell spoke to BioVox about his personal reasons for founding the company and why Belgium is such an attractive location to start-ups in the medical sector.
The microbiome had been at the forefront of a lot of research and news in the past few years. Now, a new study published in Nature Microbiology has linked specific microbiome changes with depression and quality of life. The largest of its kind to-date, the research was made possible by over 2000 participants from the Flemish Gut Flora Project and the Dutch LifeLines DEEP project. The results may lead to novel therapies for people suffering from this debilitating mental illness.
This month marked the crystal anniversary of the life sciences networking event Knowledge for Growth. The event was a huge success, with 1300+ attendees representing 600+ companies from 20+ countries around the world. The theme for this year was “Precision in Life Sciences”, with the fascinating plenary talks discussing the effect of digitalization on healthcare.
Just days before KBC Securities’ "State of the Union" announcement on how well Belgian biotech has been faring in 2019, Confo Therapeutics closed a terrific series A financing round. The company raised 30 million euros, which will be used to accelerate their drug discovery activities using their camelid-based ConfoBody™ technology.
Belgium has once again strengthened its position as Europe's biotech leader. Today, Belgian biotech companies comprise 23 percent of the total market value of all public European biotech companies. Compared to the end of April 2018, the value of Belgian biotech companies increased by 12.5 percent from 24 to 27 billion euros. A few Belgian biotech giants such as Galapagos, argenx and UCB, are responsible for this growth. This according to figures announced by KBC Securities during the "State of the Union" event of the Flemish biotech sector federation flanders.bio and VIB on the eve of the large "knowledge for growth" congress in Ghent.
Have you ever considered how scientists are able to count transparent cells in a see-through solution? Traditional methods involve dyes, microscopes, time and effort. Now there’s a new technology on the market: Ovizio Imaging Systems has developed a technical solution to this longstanding problem. Using an imaging technique called digital holographic microscopy, Ovizio’s devices perform cell counts by reconstructing 3D images using light. This new type of imaging provides quantitative information about cells, including their number, morphology and viability, all without a drop of dye!
Bioscience engineers at KU Leuven have created a record-breaking hydrogen gas panel. The panel is capable of producing 250 liters of hydrogen gas per day; enough that just 20 panels could provide a family’s electricity and heating needs for a whole European winter. The Belgian device is an innovative step forward for clean energy and sustainability around the globe.
The Spanish start-up Minoryx Therapeutics recently opened a subsidiary in Belgium to further their research on treatments for rare and orphan diseases. Co-founder and CEO Marc Martinell spoke to BioVox about his personal reasons for founding the company and why Belgium is such an attractive location to start-ups in the medical sector.
The microbiome had been at the forefront of a lot of research and news in the past few years. Now, a new study published in Nature Microbiology has linked specific microbiome changes with depression and quality of life. The largest of its kind to-date, the research was made possible by over 2000 participants from the Flemish Gut Flora Project and the Dutch LifeLines DEEP project. The results may lead to novel therapies for people suffering from this debilitating mental illness.